A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis

Inclusion Criteria:

- Subject must have successfully enrolled in either study M10-877 or M10-880 and either
met the endpoint of "Treatment Failure" or completed the study

Exclusion Criteria:

- A subject will be excluded from this study if the patient discontinued from study
M10-877 or M10-880 for any reasons other than having a Treatment Failure event

- Subject with corneal or lens opacity that precludes visualization of the fundus or
that likely requires cataract surgery during the duration of the trial

- Subjects with intraocular pressure of >= 25 mmHg and on >= 2 glaucoma medications or
evidence of glaucomatous optic nerve injury

- Subject with proliferative or severe non-proliferative diabetic retinopathy or
clinically significant macular edema due to diabetic retinopathy

- Subject with neovascular/wet age-related macular degeneration

- Subject with abnormality of vitreo-retinal interface (i.e., vitreomacular traction,
epiretinal membranes, etc.) with the potential for macular structural damage
independent of the inflammatory process

- Subject with a systemic inflammatory disease that requires therapy with a prohibited
immunosuppressive agent at the time of study entry